根据治疗策略的IIIC宫癌生存结果:系统性审查和元分析
Yi-Xiang Li1,2, Si-Yu Cao1,2, Yu Fan1,2
1Department of Gynaecology and Obstetrics, West China Second Hospital, Sichuan University, No. 20, Sect. 3, Renminnan Road, Chengdu, 610041, Sichuan, People's Republic of China.
在IIIC期子宫癌患者中,激进化疗 (RCRT) 和激进切除子宫 (RH) 的生存结果相似. 由于目前研究的多样性,需要进一步的研究.
科学领域:
- 妇科瘤学
- 临床瘤学
- 基于证据的医学
背景情况:
- 宫癌IIIC阶段存在复杂的治疗挑战.
- 治疗策略显著影响患者的生存结果.
- 进行激进切除术 (RH) 和激进化疗 (RCRT) 的比较对于优化护理至关重要.
研究的目的:
- 为了比较RH和RCRT之间的存活结果,用于IIIC期的宫癌.
- 对治疗疗效的现有数据进行系统审查和元分析.
- 提供临床决策和治疗指南.
主要方法:
- 在PubMed,科学网,CNKI和万芳的系统文献搜索.
- 对生存结果的危险比率 (HR) 的元分析.
- 使用I2统计的异质性评估.
主要成果:
- 分析了9项涉及6793名患者的研究 (RH: 56. 5%,RCRT: 43. 5%).
- 在各个研究中观察到很高的异质性 (所有结果的I2> 80%).
- 在整体存活率 (HR 0. 77),无病存活率 (HR 0. 68) 或无进展存活率 (HR 0. 67) 之间没有统计学意义上的差异.
结论:
- 目前的证据表明,在IIIC期子宫癌中,RCRT与RH没有显著的生存优势.
- 这些发现与NCCN的建议一致,但需要谨慎的解释.
- 高异质性和宽置信区间需要对患者群体和治疗变异进行进一步的研究.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
相关概念视频
Cancer Survival Analysis
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy
Comparing the Survival Analysis of Two or More Groups
Treatment Resistant Cancers
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
